Loading
collectionsCollection
NICE cancer guidance and technology appraisals (UK)
NICE decides which cancer treatments the NHS pays for, publishing for each drug an appraisal of cost per quality-adjusted life year against a threshold of £25,000 to £35,000, plus clinical guidelines. Because the manufacturer models and committee reasoning are public, its decisions serve as an independent view of a drug's value that often diverges from FDA and EMA licensing.
Overview
NICE technology appraisals (since 1999) assess clinical and cost-effectiveness against a threshold of £25,000-35,000 per QALY since 2 April 2026, raised from £20,000-30,000 (with severity modifiers, which replaced the end-of-life rule in 2022), and can recommend, restrict, or route drugs to the Cancer Drugs Fund for data collection. Clinical guidelines (e.g. NG12 suspected cancer recognition and referral) set diagnostic pathways. Appraisal documents contain manufacturer models, evidence review group critiques and committee reasoning, making them one of the most transparent public sources on drug value; decisions often diverge from FDA/EMA licensing.
Holds
UK clinical guidelines (NG series), technology appraisals with cost-effectiveness decisions for every new cancer drug (including Cancer Drugs Fund managed access), quality standards and pathways.
Licence
Open Government Licence / NICE terms
Maintainer
National Institute for Health and Care Excellence
Similar pages
- CollectionCSCO guidelines (China)
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag guidelines.
- InstitutionScottish Medicines Consortium
Shares NICE technology appraisal methods (2022), ILAP (Innovative Licensing and Access Pathway), National Institute for Health and Care Excellence.
- PersonMichael LeBlanc
Shares Hazard ratio (HR), Progression-free survival (PFS), Overall survival (OS).
- PersonJonathan Benger
Shares Health technology assessment (HTA), reimbursement and QALYs, National Institute for Health and Care Excellence.
- TermClinical benefit response (the gemcitabine trial endpoint)
Shares Hazard ratio (HR), Progression-free survival (PFS), Overall survival (OS).
- IdeaGuidelines list the open trials at every decision point, updated monthly
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
- CollectionNICE technology appraisals
Shares National Institute for Health and Care Excellence, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
- IdeaAlert guidelines and trials when a paper they rely on is retracted
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
institutions
terms
Cancer Drugs Fund (England)Hazard ratio (HR)Health technology assessment (HTA), reimbursement and QALYsILAP (Innovative Licensing and Access Pathway)Innovative Medicines Fund (England)NICE technology appraisal methods (2022)Oncology drug pricing and price transparencyOverall survival (OS)Progression-free survival (PFS)